Accelerated Aging in Newborns and Adults With Congenital Heart Disease

Heart Defects, Congenital Clinical Trial

— AccelerAGE  

Official title:

A Lifespan Perspective on Accelerated Aging in Congenital Heart Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05667870
• Other study ID #: S66590
• Status: Recruiting
• Start date: February 20, 2023
• Est. completion date: June 2025

Study information

• Verified date: June 2023
• Source: KU Leuven
• Contact: Philip Moons, PhD, RN
• Phone: 016/373315
• Email: philip.moons[@]kuleuven.be
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Many childhood-onset diseases used to be lethal. Improved life expectancy yield that most patients can survive into adulthood, to date. However, survivors of childhood-onset diseases often develop morbidities that suggest accelerated aging. Indeed, age-related conditions are observed sooner and more frequently in people with childhood-onset diseases. Congenital heart disease (CHD) is a typical example of a childhood-onset disease and is the most common birth defect, comprising a spectrum of mild, moderate and complex heart defects. Recent studies showed that age-related morbidities occur more often and at an earlier age in these patients. The overall goal of this project is to quantify and understand disparities in chronological and biological age over the lifespan in CHD patients.

Description:

Three main research objectives are proposed: Objective 1: The investigators will determine the biological age in patients with CHD across the lifespan, using established and novel biomarkers for aging, and assess the disparity with chronological age. Objective 2: The investigators will identify clinical, behavioral, psychological and social predictors of aging in patients with CHD. Objective 3: The investigators will investigate the difference in biological-chronological age disparity between patients with CHD and healthy counterparts. Three studies will be performed to investigate these objectives: Study 1: Newborns with CHD - The aim is to (i) compare telomere length in newborns with or without CHD; and (ii) to assess pregnancy-related/clinical and mother-related (behavioral, psychological, social) predictors of telomere length in newborns with CHD. Study 2: (Young) adults with CHD - This study aims to (i) compare telomere length in age strata of (young) adults with or without CHD; (ii) to assess clinical, behavioral, psychological, and social predictors of telomere length in patients with CHD; and (iii) to explore the relationship with functional outcomes, such as frailty and cognition. Study 3: Epigenetic clock in adults with CHD - This study focusses on (i) assessing the biological age by measuring DNA methylation in mild, moderate and complex heart defects, and (ii) determining if the disparity between biological and chronological age is a function of anatomical complexity and functional status of the patients and (iii) comparing the epigenetic clock of adults with and without CHD.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1200
• Est. completion date: June 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

1. Newborn with CHD and mother

Inclusion:

• Newborns with CHD who are diagnosed and born in UZ Leuven or UZ Gent
• The mother is able to adequate fill out the questionnaires
• Informed consent is signed

Exclusion:

• The mother does not speak Dutch
• The heart defect falls within a syndrome condition (e.g., Down syndrome, 22q11 deletion)
• Very mild heart defects such as a patent foramen ovale, an open ductus of Botalli (no intervention needed), spontaneous closure of ASD/VSD, an isolated mild peripheral pulmonary stenosis

2. Adults with CHD - study 2

Inclusion:

• = 18 years of age at the moment of study inclusion
• Diagnosed with CHD
• Follow-up at the UZ Leuven or UZ Gent
• Signed informed consent
• Physical, cognitive, and language abilities to complete self-report questionnaires/ assessment tests

Exclusion:

• Not speaking Dutch
• Very mild heart defects such as a patent foramen ovale, an open ductus of Botalli (no intervention needed), spontaneous closure of ASD/VSD, an isolated mild peripheral pulmonary stenosis
• The heart defect falls within a syndrome condition (e.g., Down syndrome, 22q11 deletion)

3. Adults with CHD - study 3

Inclusion:

• Included in study 2
• Between 30-50 years of age at the moment of study inclusion
• Follow-up at the UZ Leuven or UZ Gent
• Signed informed consent
• Physical, cognitive, and language abilities to complete self-report questionnaires/ assessment tests
• Having one of the following CHD conditions: isolated arterial septal defect, isolated ventricular septal defect, tetralogy of Fallot, coarctation of the aorta, Fontan operation or systemic right ventricle. Exclusion
• Not speaking Dutch
• The heart defect falls within a syndrome condition (e.g., Downsyndrome, 22q11 deletion)

4. Health volunteers

Inclusion:

• Male or female healthy volunteers of the Red Cross
• Aged 18 - 65 years at the moment of inclusion
• The healthy volunteers must match with the patients included in study 2 based on age and sex
• Signed informed consent
• The requirements of the Red Cross for blood donation are fulfilled

Exclusion:

• Medical history of cardiac, pulmonal, renal or liver disease, chronic anemia, blood clotting disorder
• Not speaking Dutch
• Pregnancy
• Born with a heart condition

Related Conditions & MeSH terms

• Congenital Abnormalities
• Heart Defects, Congenital
• Heart Diseases

Locations

Country	Name	City	State
Belgium	Ghent University Hospital	Ghent
Belgium	University Hospital Leuven	Leuven

Sponsors (3)

Lead Sponsor	Collaborator
KU Leuven	Hasselt University, University Hospital, Ghent

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Telomere length	Telomere length will be measured on umbilical cord blood from newborns and on peripheral blood from adults with and without CHD.	Baseline
Secondary	Clinical, behavioral, psychological and social predictors of telomere length	This will be studied by using the life history calendar in adults. In newborns, a pregnancy history calendar and correlation with the maternal telomere length will be used.	Baseline
Secondary	Fall history as a functional outcome of aging in adults with CHD	A fall history questionnaire will be used.	Baseline
Secondary	Frailty as a functional outcome of aging in adults with CHD	The Fried method is used for assessment of frailty and consists of five parts: self-report questions about unintentional weight loss, exhaustion and physical activity, an assessment of weakness performed using a handgrip dynamometer, and a walk test. A patient is considered non-frail, pre-frail and frail if, respectively, 0, 1-2 or 3/more components are present.	Baseline
Secondary	Cognitive impairment as a functional outcome of aging in adults with CHD	The Montréal Cognitive Assessment Screener (MoCA) is used for assessment of cognitive function. The maximum score is 30 points, a score of 26 or higher is considered normal. A lower score indicates a worse cognitive function.	Baseline
Secondary	Epigenetic clock in adults with and without CHD	This will be examined based on DNA methylation.	Baseline
Secondary	hsCRP in adults with CHD		Baseline
Secondary	Retina scan in adults with CHD	This will only be performed on patients included in Leuven	Baseline